Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

Ref: MHL/Sec&Legal/2026-27/32 August 04, 2026 BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Outcome of Board Meeting held on Tuesday, August 04, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations’), this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Tuesday, August 04, 2026, approved the unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2026, and noted the limited review report thereon, issued by the Statutory Auditors of the Company. The financial results together with the limited review report are enclosed herewith. The financial results are also being made available on the Company’s website at www.metropolisindia.com. Further, the Board of Directors noted that the sale and transfer of External Quality Assessment Services Business of the Company to Metropolis Quality Solutions Private Limited, wholly owned subsidiary of the Company, which was originally scheduled to be completed within 6 (six) months of execution of the Business Transfer Agreement dated February 04, 2026, is now expected to take an additional 2 (two) months. The meeting commenced at 02:00 p.m. (IST) and concluded at 05:20 p.m. (IST). You are requested to take the above information on record. Thanking you, Yours faithfully, For Metropolis Healthcare Limited Kamlesh C Kulkarni Head - Legal & Secretarial Encl: a/a BSR&Co. LLP Western Express Highway Chartered Accountants Goregaon (East), Mumbai — 400 063, India Telephone: +91 (22) 6257 1000 Fax: +91 (22) 6257 1010 Limited Review Report on unaudited standalone financial results of Metropolis Healthcare Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Metropolis Healthcare Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis Healthcare Limited (hereinafter referred to as “the Company”) for the quarter ended 30 June 2026 ("the Statement’). This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting’ (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’). Our responsibility is to issue a report on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year, The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it Registered Office: BSR &Co. (a partnership firm with Registration No. BAG1223) converted into B S R & Co. LLP (a 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 2 BSR&Co. LLP Limited Review Report (Continued) Metropolis Healthcare Limited contains any material misstatement. ForBSR& Co. LLP Chartered Accountants Firm’s Registration No.:101248W/W-100022 Rajesh Mehra Partner Mumbai Membership No.: 103145 04 August 2026 UDIN:2610314500GHIR2438 Page 2 of 2 METROPOLIS Metropolis Healthcare Limited Registered Office: 4th Floor, East Wing, Plot 254 B. Nirlon House, Dr.Annie Besant Road, Worli. Mumbai - 400030, Maharashtra, India CIN:L73100MH2000PLC 192798 Contact Ne.: 8422 801 801, Email: supporta:metropolisindia.com, Website: www.melropolisindia.com Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070, Maharashtra, India Si of i Fi ‘ial Results for the quarter ended 30 June 2026 (Rs. in millions) Quarter ended Year Ended Sr.No. Particulars 30 June 2026 | 31 March 2026 | 30 June 2025} 31 March 2026 (Unaudited) (Andited) (Unaudited) (Audited) (Refer note:2) Continuing operation i} Income a) Revenue from operations 3,722.84 3,520.31 3,232.69 _ 13,654.72 'b) Other income 51.86 88.17 27.79 163.31 Total Income 3,774.70 3,608.48 3,260.48 13,818.03 2 |Expenses a) Cost of materials consumed 684.74 608.18. 613.58 2,527.18 'b) Laboratory testing charges 67.68 56.90, 40.55 180.18 c) Employee benefits expense $52.43, 749.28 722.69 2,974.38 d) Finance costs 473 65.61 42.93 191.87 e) Depreciation and amortisation expense 278.06 327.97 278.60 1,161.67 f) Other expenses 1.180.30 1.204.43 | 1,088.29 4,590.75, Total Expenses ; 3,110.94 3,012.37 2,786.64 11,626.03 3 |Profit before exceptional items and tax (1) - (2) 663.76 596.11 473.84 2,192.00 4° |Exceptional [tems (Refer note 9} = - : 79.57 5 |Profit before tax (3) - (4) 663.76 596.11 473.84 2,112.43 6 | Tax expenses Current tax : -for the period / year: 168.78 188.96 131.76 STLRG -tax adjusted for earlier years: - = 3.70 3.70 Deferred tax credit G1.56)| (25.45)| (5.21) __ G4.55) Total tax expenses (Net) 157.22 163.51 || 120.25 541.01 7 |Profit for the period / year from continuing operations (5) - (6) 506.54 432.60 353.59 1,571.42 8 |Discontinued Operations (Loss)/Profit from discontinued operation (0.95) (0.33) 2.98 ASR Tax expense ofd iscontinued operations (0.24) (0.08) 0.75 115 Profit from discontinued operations (after tax) (0.71) (0.25) 2.23 3.43 9 — {Profit for the period/year (7) + (8) $05.83 432.35 355.82 1,574.85 10 [Other comprehensive income Mems that will not be reclassified subsequently to profit and loss (net of tax) 0.44 441 (4.20) (1.75) OIt te hm es r t cha ot m pwi rl el h b ee n ssu ib vs ee q iu ne cn ot ml ey r fe oc rl a ts hs ei f pi ee rd i oto d p fr yo efi at r a (n ned t l oo fs s t a(n xe )t of tax) 0= .44 4= 41 (4a . 20) (1= . 75) 11 |Total comprehensive income (9) + (10) 506.27) 436.76) 351.62, 1,573.10) 12 |Paid-up equity share capital (face value - Rs. 2 per share) 414.67 414.66 103.61 414.66 13° | Other equity - - = 13.476.40 14 | Earning per share from continuing operation Eamings per share (Face value of Rs.2 [Showing first 8,000 characters — download PDF for full document]